Grape seed extract supplementation in non-alcoholic fatty liver disease

被引:2
|
作者
Ghanbari, Parisa [1 ]
Alboebadi, Roghayeh [1 ]
Bazyar, Hadi [2 ,3 ]
Raiesi, Davoud [4 ]
Zarejavid, Ahmad [5 ]
Azadbakht, Mohammad Karim [6 ]
Karimi, Mahdi [1 ]
Razmi, Hamidreza [1 ]
机构
[1] Ahvaz Jundishapur Univ Med Sci, Student Res Comm, Ahvaz, Iran
[2] Sirjan Sch Med Sci, Dept Publ Hlth, Sirjan, Iran
[3] Student Res Comm, Sirjan Sch Med Sci, Sirjan, Iran
[4] Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Internal Med, Ahvaz, Iran
[5] Ahvaz Jundishapur Univ Med Sci, Clin Sci Res Inst, Nutr & Metab Dis Res Ctr, Ahvaz, Iran
[6] Sirjan Sch Med Sci, Dept Basic Sci, Sirjan, Iran
关键词
non-alcoholic fatty liver disease; oxidative stress; quality of life; grape seed extract; ANTIOXIDANT STATUS; OXIDATIVE STRESS; DOUBLE-BLIND; INCREASES; QUESTIONNAIRE; POLYPHENOLS; VALIDATION;
D O I
10.1024/0300-9831/a000805
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Despite rising non-alcoholic fatty liver disease (NAFLD) prevalence and its impact on liver health, there's a lack of studies on grape seed extract's (GSE) effect on oxidative stress and quality of life (QoL) in NAFLD patients. This study aims to fill this gap by the potential benefits of GSE in reducing oxidative stress and improving QoL. Methods: In this randomized clinical trial study, fifty patients with NAFLD were randomly assigned to receive either 2 tablets of GSE containing 250 mg of proanthocyanidins or placebo (25 participants in each group) for two months. QoL was evaluated using the SF-36 questionnaire, and oxidative stress variables (TAC, MDA, SOD, GPx, CAT, and IL-6) were measured at the beginning and end of the study. Results: Compared with the control group, the group supplemented with GSE experienced greater reductions in IL-6 and MDA (3.14 +/- 1.43 pg/ml vs. 2.80 +/- 0.31 pg/ml; 4.16 +/- 2.09 mu M vs. 4.59 +/- 1.19 mu M, p for all <0.05), as well as greater increases in TAC, SOD, and GPx levels (0.18 +/- 0.08 mM vs. -0.03 +/- 0.09 mM; 10.5 +/- 6.69 U/ml vs. 8.93 +/- 1.63 U/ml; 14.7 +/- 13.4 U/ml vs. 8.24 +/- 3.03 U/ml, p for all <0.05). Furthermore, the QoL questionnaire showed that physical limitations, general health, and total physical health were significantly improved in the GSE group compared with the placebo (17.0 +/- 42.0 vs. -12.0 +/- 37.5; 3.80 +/- 14.8 vs. -3.92 +/- 9.55; 5.08 5.26 vs. -7.01 +/- 13.7, p for all <0.05). Conclusions: GSE can be effective in improving oxidative stress and QoL in patients with NAFLD. More studies are needed to confirm the results of this study.
引用
收藏
页码:365 / 376
页数:12
相关论文
共 50 条
  • [41] Increase in liver antioxidant enzyme activities in non-alcoholic fatty liver disease
    Perlemuter, G
    Davit-Spraul, A
    Cosson, C
    Conti, M
    Bigorgne, A
    Paradis, V
    Corre, MP
    Prat, L
    Kuoch, V
    Basdevant, A
    Pelletier, G
    Oppert, JM
    Buffet, C
    LIVER INTERNATIONAL, 2005, 25 (05) : 946 - 953
  • [42] Dissecting the role of cadmium, lead, arsenic, and mercury in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Tinkov, Alexey A.
    Aschner, Michael
    Santamaria, Abel
    Bogdanov, Alfred R.
    Tizabi, Yousef
    Virgolini, Miriam B.
    Zhou, Ji-Chang
    V. Skalny, Anatoly
    ENVIRONMENTAL RESEARCH, 2023, 238
  • [43] Protein glutathionylation increases in the liver of patients with non-alcoholic fatty liver disease
    Piemonte, Fiorella
    Petrini, Stefania
    Gaeta, Laura Maria
    Tozzi, Giulia
    Bertini, Enrico
    Devito, Rita
    Boldrini, Renata
    Marcellini, Matilde
    Ciacco, Enzo
    Nobili, Valerio
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 (08) : E457 - E464
  • [44] Current treatment of non-alcoholic fatty liver disease
    Ahmed, Mohamed H.
    Byrne, Christopher D.
    DIABETES OBESITY & METABOLISM, 2009, 11 (03) : 188 - 195
  • [45] Current management of non-alcoholic fatty liver disease
    Lisboa, Quelson Coelho
    Ferolla Costa, Silvia Marinho
    Couto, Claudia Alves
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2016, 62 (09): : 872 - 878
  • [46] A concise review of non-alcoholic fatty liver disease
    Than, Nwe Ni
    Newsome, Philip N.
    ATHEROSCLEROSIS, 2015, 239 (01) : 192 - 202
  • [47] The Role of Fucoxanthin in Non-Alcoholic Fatty Liver Disease
    Winarto, Jessica
    Song, Dae-Geun
    Pan, Cheol-Ho
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (09)
  • [48] Effects of green coffee extract supplementation on glycemic indexes, leptin, and obesity values in patients with non-alcoholic fatty liver disease
    Hosseinabadi, Samaneh
    Rafraf, Maryam
    Mahmoodzadeh, Abolfazl
    Asghari-Jafarabadi, Mohammad
    Asghari, Somayyeh
    JOURNAL OF HERBAL MEDICINE, 2020, 22
  • [49] Non-alcoholic fatty liver disease: A sign of systemic disease
    Reccia, Isabella
    Kumar, Jayant
    Akladios, Cherif
    Virdis, Francesco
    Pai, Madhava
    Habib, Nagy
    Spalding, Duncan
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2017, 72 : 94 - 108
  • [50] Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet
    Abenavoli, Ludovico
    Milic, Natasa
    Peta, Valentina
    Alfieri, Francesco
    De Lorenzo, Antonino
    Bellentani, Stefano
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (45) : 16831 - 16840